World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
18592
World Ranking
18538
National Ranking
617

Overview

Michel Henry-Amar is affiliated with the Université de Caen Normandie in France and has contributed mainly to the field of Medicine, with a focus on epidemiology, economics and econometrics, pathology and forensic medicine, oncology, and genetics.

Their research centers on multiple and secondary primary cancers, lymphoma diagnosis and treatment, global cancer incidence and screening, BRCA gene mutations in cancer, thyroid cancer diagnosis and treatment, and economic and financial impacts of cancer as well as health systems, economic evaluations, and quality of life.

Prominent papers authored or coauthored by Michel Henry-Amar include:

  • "Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment," 2022, British Journal of Cancer
  • "Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials," 2022, Journal of Cancer Survivorship
  • "Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials," 2023, Acta Oncologica
  • "Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study," 2021, Cancer

Frequent coauthors include:

  • Olivier Casasnovas
  • Sidsel J. Juul
  • Sára Rossetti
  • Michal Kiciński
  • Marleen A. E. van der Kaaij

Their work has been published in the following venues:

  • British Journal of Cancer
  • Cancer
  • Journal of Cancer Survivorship
  • Acta Oncologica

Best Publications

  • Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

    J M Coindre;P Terrier;N B Bui;F Bonichon

  • Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

    Socié G;Henry-Amar M;Bacigalupo A;Hows J

  • Leukemia following Hodgkin's disease.

    Kaldor Jm;Day Ne;Clarke Ea;Van Leeuwen Fe

  • Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

    Christophe Fermé;Houchingue Eghbali;Jacobus H. Meerwaldt;Chantal Rieux

  • Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients

    HJ Deeg;G Socie;G Schoch;M Henry-Amar

  • Involved-field radiotherapy for advanced Hodgkin's lymphoma.

    Berthe M.P. Aleman;John M.M. Raemaekers;Umberto Tirelli;Roberto Bortolus

  • Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

    H Tilly;S Castaigne;D Bordessoule;P Casassus

  • Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

    M Tubiana;M Henry-Amar;P Carde;JM Burgers

  • Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease

    M. Henry-Amar

  • Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials

    Evert M. Noordijk;Patrice Carde;Noëlle Dupouy;Anton Hagenbeek

  • Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

    Jeremy Franklin;A. Pluetschow;M. Paus;L. Specht

  • Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma.

    Stéphane Bardet;Elodie Malville;Jean-Pierre Rame;Emmanuel Babin

  • Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

    P Carde;J M Burgers;M Henry-Amar;M Hayat

  • Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia.

    Socié G;Henry-Amar M;Cosset Jm;Devergie A

  • Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients

    Marc P Andre;Nicolas Mounier;Xavier Leleu;Anne Sonet

  • Quality of Life in Long-Term Survivors of Testicular Cancer: A Population-Based Case-Control Study

    F. Joly;J. F. Héron;L. Kalusinski;P. Bottet

  • Pericarditis and myocardial infarctions after Hodgkin's disease therapy

    J.M. Cosset;M. Henry-Amar;B. Pellae-Cosset;P. Carde

  • Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma: a multivariate analysis, report of 106 cases, and review of the literature

    Mohamed B. Azab;Michel Henry-Amar;Philippe Rougier;Caroline Bognel

  • Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study

    Marc Andre;Michel Henry-Amar;Jose-Luis Pico;Pauline Brice

  • Treatment-Related Deaths and Second Cancer Risk After Autologous Stem-Cell Transplantation for Hodgkin's Disease

    Marc André;Michel Henry-Amar;Didier Blaise;Philippe Colombat

Frequent Co-Authors

Hanneke C. Kluin-Nelemans
Hanneke C. Kluin-Nelemans University Medical Center Groningen
Hervé Tilly
Hervé Tilly Grenoble Alpes University
Umberto Tirelli
Umberto Tirelli National Institutes of Health
Jean-Yves Douillard
Jean-Yves Douillard European Society for Medical Oncology
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Lena Specht
Lena Specht University of Copenhagen
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Christian Gisselbrecht
Christian Gisselbrecht Université Paris Cité
André Tichelli
André Tichelli University Hospital of Basel
Volker Diehl
Volker Diehl University of Cologne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Medicine, there are a variety of online degrees and career advancement pathways that can help you meet your educational and professional goals. Many healthcare professionals and aspiring clinicians are seeking flexible options to further their expertise, especially through fully online programs.

CAHME accredited MHA online programs are ideal for those who want to move into healthcare administration or management, providing essential skills in leadership, healthcare policy, and organizational strategy. Nurses looking to advance without time-consuming commutes or in-person requirements may consider online RN-BSN programs without clinicals, offering a streamlined path to the BSN credential.

For advanced nursing practice, you can accelerate your studies with accelerated MSN to DNP programs, designed to fast-track your progress to a terminal nursing degree. Those seeking more flexible options may benefit from the growing selection of DNP programs online, which allow working professionals to balance study, work, and life.

Exploring these accredited programs can open new doors in healthcare—whether you are stepping into administration, broadening your nursing expertise, or reaching the pinnacle of clinical practice.

Best Scientists Citing Michel Henry-Amar

Trending Scientists